# A Research Study Looking Into Levels of the Medicine NNC0385-0434 in the Body and How Well it is Tolerated in Participants With Impaired Kidney Function Compared to Participants With Normal Kidney Function

> **NCT05094934** · PHASE1 · TERMINATED · sponsor: **Novo Nordisk A/S** · enrollment: 60 (actual)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** NNC0385-0434 A 100 mg

## Key facts

- **NCT ID:** NCT05094934
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-09
- **Primary completion:** 2022-07-15
- **Final completion:** 2022-08-24
- **Target enrollment:** 60 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2023-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05094934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05094934, "A Research Study Looking Into Levels of the Medicine NNC0385-0434 in the Body and How Well it is Tolerated in Participants With Impaired Kidney Function Compared to Participants With Normal Kidney Function". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05094934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*